Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61008 | 0.79 | ADORA2A (0.49) | ADORA2AADORA1HRH3RAB9ASMN1; SMN2 | |
| SCHEMBL29893499 | 0.79 | AXL (0.39) | ADORA2AADORA1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL55302 | 0.79 | AXL (0.39) | ADORA2AADORA1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL1367259 | 0.78 | AXL (0.52) | ADORA2AADORA1HRH3RAB9ASMN1; SMN2 | |
| SCHEMBL13236422 | 0.76 | ADORA2A (0.53) | ADORA2AADORA1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL8945519 | 0.76 | AXL (0.37) | ADORA2AADORA1RAB9ANPC1HTT | |
| SCHEMBL24170311 | 0.76 | ADORA2A (0.50) | ADORA2AADORA1HRH3RAB9ASMN1; SMN2 | |
| SCHEMBL30277827 | 0.76 | ADORA2A (0.50) | ADORA2AADORA1HRH3RAB9ASMN1; SMN2 | |
| SCHEMBL19661007 | 0.76 | ADORA2A (0.46) | ADORA2AADORA1HRH3RAB9ASMN1; SMN2 | |
| SCHEMBL18701478 | 0.76 | ADORA2A (0.56) | ADORA2AADORA1HTTAXLMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2710018-B1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | FUNDACION CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2021-12-29 | — | — | EP | disclosed |
| EP-3399968-B1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LTD (KY) | 2021-10-20 | — | — | EP | disclosed |
| US-9808466-B2 | Macrocyclic compounds as protein kinase inhibitors | FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III | 2017-11-07 | — | — | US | disclosed |
| US-9808466-B2 | Macrocyclic compounds as protein kinase inhibitors | FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III | 2017-11-07 | — | — | US | disclosed |
| WO-2017120429-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmasciences, Inc. (US) | 2017-07-13 | — | — | WO | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20160296528-A1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2016-10-13 | — | — | US | disclosed |
| US-20160296528-A1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2016-10-13 | — | — | US | disclosed |
| US-9284334-B2 | Macrocyclic compounds as protein kinase inhibitors | FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2016-03-15 | — | — | US | disclosed |
| EP-2964654-A1 | THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS | Glaxosmithkline LLC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20070213305-A1 | N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007056214-A2 | N-ALKYL-N-ARYL-THIENOPYRIMIDIN-R-AMINES AND USES THEREOF | CYTOVIA, INC (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056214-A2 | N-ALKYL-N-ARYL-THIENOPYRIMIDIN-R-AMINES AND USES THEREOF | CYTOVIA, INC (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070099877-A1 | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099877-A1 | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099877-A1 | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| EP-1192164-B1 | THIENO- AND FUROPYRIMIDINE DERIVATIVES AS A2A-RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2005-08-17 | — | — | EP | disclosed |
| US-6787541-B1 | MOVEMENT DISORDERS, PARKINSON'S DISEASE | VERNALIS RESEARCH LIMITED (GB) | 2004-09-07 | — | — | US | disclosed |
| EP-1192164-A1 | THIENO- AND FUROPYRIMIDINE DERIVATIVES AS A2A-RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001002409-A1 | THIENO- AND FUROPYRIMIDINE DERIVATIVES AS A2A-RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213305-A1 | N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP10, CASP4, CASP3 | ADORA2A 237/4885ADORA1 259/4885HRH3 254/4885 |
| US-20160296528-A1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | PIM1, PIM3, PIM2 | ADORA2A 4307/4885ADORA1 4195/4885HRH3 3191/4885 |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | ADORA2A 1159/4885ADORA1 1353/4885HRH3 1072/4885 |
| US-20070099877-A1 | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP4, CASP3, API5 | ADORA2A 249/4885ADORA1 241/4885HRH3 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.